last
decad
revolut
drug
industri
due
develop
medicin
chemistri
studi
basic
caus
develop
differ
diseas
develop
medicin
chemistri
reward
bowen
zhong
greatli
facilit
develop
drug
understand
mechan
drug
action
usual
sens
medicin
chemistri
simpli
meant
applic
organ
chemistri
drug
synthesi
umbrella
come
variou
aspect
drug
design
identif
metabolit
studi
enzym
respons
differ
diseas
comput
chemistri
studi
threedimension
structur
molecul
enzym
studi
physicochem
properti
drug
molecul
topolog
develop
quantit
structureact
relationship
molecular
model
xray
crystallographi
nuclear
magnet
reson
nmr
molecular
dynam
gupta
thu
research
direct
design
develop
drug
includ
medicin
chemistri
medicin
chemistri
organ
chemistri
chemistri
depart
chemist
use
find
way
synthesi
particular
drug
becom
valuabl
subject
pharmaci
depart
name
pharmaceut
chemistri
pharmacist
focu
medicin
chemistri
understand
predict
chang
molecular
structur
lead
enhanc
biolog
activ
medicin
chemist
view
medicin
chemistri
strictli
applic
orient
thu
medicin
chemistri
complex
scienc
gone
beyond
hand
classic
organ
chemist
career
medicin
chemistri
becom
reward
challeng
today
medicin
chemist
expect
knowledg
organ
chemistri
also
caus
diseas
biolog
interfac
medicin
chemistri
combin
form
set
highli
interdisciplinari
scienc
encompass
synthet
chemistri
comput
chemistri
spectroscopi
enzymolog
virolog
microbiolog
toxicolog
etc
thu
medicin
chemistri
play
signific
role
design
develop
drug
chapter
present
experiment
theoret
role
medicin
chemistri
design
antihepat
drug
virolog
provid
enough
inform
regard
life
cycl
differ
lifethreaten
virus
crucial
step
necessari
replic
crucial
step
involv
differ
polymeras
proteas
could
found
import
target
design
potent
antivir
drug
describ
exploit
polymeras
proteas
could
success
util
design
drug
five
hepat
virus
hepat
viru
hav
hepat
e
viru
hev
howev
chapter
chosen
discuss
drug
hav
hepat
viru
hdv
hev
less
studi
compar
hepat
b
viru
hbv
hepat
c
viru
design
antihav
drug
target
extens
exploit
proteas
hav
picornavir
cystein
proteas
essenti
cleavag
initi
synthes
viral
polyprotein
precursor
matur
fragment
therefor
requir
viral
replic
vivo
huang
et
al
observ
proteas
cleav
two
peptid
correspond
viral
polyprotein
junction
effici
jewel
et
al
gener
recogn
peptid
substrat
lglutamin
site
cystein
proteas
usual
adopt
chymotrypsinlik
fold
allair
et
al
matthew
et
display
activ
site
configur
like
serin
proteas
specif
mostli
peptidebas
compound
studi
hav
inhibitor
howev
far
follow
differ
type
inhibitor
studi
peptid
aldehyd
inhibitor
b
azaglutamin
ketoglutamin
deriv
huang
et
al
ramtohul
et
al
c
azodicarboxamid
hill
vedera
pseudoxazolon
ramtohul
et
al
e
serin
threonin
blacton
lall
et
al
lall
et
al
f
triazolo
pyridazin
shamroukh
ali
g
heteroaromat
ester
huitema
et
al
peptid
aldehyd
inhibitor
develop
peptid
aldehyd
inhibitor
base
modif
acetylleualaala
sequenc
act
competitor
natur
substrat
leuargthr
jewel
et
al
malcolm
et
al
basi
monofluoromethylketon
fmk
also
develop
inhibitor
morri
et
al
found
fmk
complex
hav
coval
bond
catalyt
cystein
yin
et
al
common
featur
substrat
requir
recognit
proteas
found
glutamin
residu
posit
krausslich
wimmer
pn
refer
bind
site
left
right
side
scissil
peptid
bond
respect
correspond
bind
site
substrat
refer
sn
respect
substrat
replac
glutamin
alanin
found
act
substrat
jewel
et
al
variou
consider
malcolm
et
al
studi
four
peptid
aldehyd
inhibitor
inhibitor
acetyl
n
ndimethylglutamin
acq
h
acetyl
leucinylalanylalanyl
n
n
dimethylglutamin
aclaaq
h
thioester
precursor
aclaaq
set
relat
peptid
aldehyd
acetyl
alanylalanylalanyl
n
ndimethylglutamin
acaaaq
h
compound
acetyl
leucinylalanylalanyl
n
n
dimethylglutamin
aclaaq
h
found
activ
inhibitor
leucin
l
residu
replac
alanin
residu
result
fivefold
loss
activ
sinc
hav
gener
recogn
peptid
substrat
lglutamin
site
four
type
analog
azaglutamin
residu
shown
fig
b
c
chemic
synthes
huang
et
al
compound
hydrazoonitrophenylsulfenamid
frameshift
hydrazoonitrophenylsulfenamid
b
azaglutamin
sulfonamid
c
haloacetyl
azaglutamin
analog
gener
inhibitor
proteas
includ
cystein
proteas
incorpor
hydrazin
function
peptid
backbon
azapeptid
shown
crucial
han
janda
et
al
abel
medicin
chemistri
antihepat
agent
antihav
antihdv
antihev
agent
magrath
howev
huang
et
al
examin
number
sulfurcontain
azaglutamin
deriv
potenti
inhibitor
hav
provid
synthet
access
four
type
azaamino
acid
peptid
analog
shown
fig
among
group
compound
one
compound
belong
group
b
acleualaala
two
compound
belong
group
x
cl
x
br
found
activ
hav
compound
found
irrevers
react
activ
site
thiol
proteas
therefor
unreason
expect
substrat
analog
may
develop
act
potent
inhibitor
sinc
enzym
recogn
peptid
substrat
glutamin
residu
site
number
ketonecontain
glutamin
compound
also
synthes
test
ramtohul
et
al
inhibit
activ
hav
crystal
structur
hav
determin
bergmann
et
al
found
twodomain
bbarrel
fold
characterist
chymotrypsinlik
serin
proteinas
gorbalenya
snijder
malcolm
hav
activ
site
cystein
act
nucleophil
assist
histidin
residu
behav
gener
acidbas
catalyst
lead
format
tetrahedr
intermedi
promot
electrophil
oxyanion
hole
gorbalenya
snijder
bind
substrat
four
five
residu
preced
scissil
bond
two
three
residu
follow
found
involv
ramtohul
et
al
schechter
berger
addit
enzymesubstr
interact
also
shown
involv
hydrogen
bond
carbonyl
oxygen
enzym
substrat
gorbalenya
snijder
malcolm
search
potenti
therapeut
lead
develop
potent
inhibitor
varieti
compound
mention
earlier
section
tri
seri
ketoglutamin
analog
inhibitor
studi
ramtohul
et
al
final
design
potent
compound
inhibit
constant
ki
equal
mm
activ
compound
affect
presenc
excess
dithiothreitol
dtt
indic
type
phthalhydrazido
system
could
specif
inhibitor
hav
would
react
inadvert
ubiquit
thiol
eg
glutathion
addit
compound
suggest
author
interest
lead
structur
could
modifi
gener
drug
candid
picornavir
cystein
proteas
hill
vedera
studi
group
azodicarboxamid
hav
inhibitor
among
compound
shown
fig
found
good
inhibit
activ
four
compound
activ
micromolar
rang
mm
respect
hill
vedera
argu
compound
inhibit
proteas
format
coval
complex
enzym
activ
compound
model
activ
site
hav
base
upon
cocryst
structur
hav
coval
addit
acetylvalpheamid
cy
observ
carbonyl
oxygen
hydrogen
bond
backbon
nitrogen
residu
neither
appear
fall
oxyanion
hole
canon
form
hydrogen
bond
nitrogen
fig
also
phenyl
ring
compound
appear
fulli
enter
pocket
rigid
compound
rel
peptid
azodicarboxamid
suggest
potenti
use
cocrystal
studi
sinc
recognit
element
could
built
onto
either
side
azo
moieti
span
p
site
activ
site
usual
cystein
proteas
inhibitor
util
recognit
one
side
activ
site
hill
vedera
pseudoxazolon
repres
fig
studi
ramtohul
et
al
entir
seri
compound
found
highest
activ
ic
valu
mm
respect
enzym
inactiv
compound
suggest
involv
coval
modif
activ
site
cystein
residu
nucleophil
addit
thiolat
imin
moieti
compound
howev
pseudoxazolon
found
complet
lose
activ
presenc
dtt
indic
ad
thiol
react
rapidli
compound
compound
assum
use
drug
candid
without
consider
modif
ramtohul
et
al
howev
suggest
valuabl
biochem
tool
deriv
import
inform
enzymeinhibitor
interact
lall
et
al
studi
blacton
function
enantiomer
serin
deriv
find
effect
hav
inhibit
found
compound
could
display
good
irrevers
revers
inhibit
respect
enzym
work
base
fact
mani
natur
occur
blacton
possess
potent
biolog
activ
pommier
pon
yang
romo
abil
thiol
open
fourmemb
ring
nucleophil
attack
either
carbonyl
bposit
might
use
make
irrevers
inhibitor
cystein
proteas
two
compound
howev
ncbzserin
blacton
despit
absenc
glutamin
side
chain
import
substrat
recognit
compound
found
good
timedepend
irrevers
inhibitor
hav
k
inact
min
k
kinactk
min
enzym
concentr
mm
enantiom
found
competit
revers
inhibitor
hav
k
equal
mm
similar
enzym
concentr
thu
lall
et
al
suggest
hav
activ
site
may
differ
mode
bind
enantiom
former
act
irrevers
inhibitor
latter
revers
inhibitor
encourag
lall
et
al
later
studi
threonin
blacton
differ
configur
b
posit
r
ch
n
ph
n
lall
et
al
among
threonin
blacton
two
dallothreonin
blacton
found
activ
hav
ic
valu
mm
respect
thu
commun
lall
et
al
lall
et
al
attempt
find
broadspectrum
inhibitor
proteas
picornavirus
coronavirus
respect
huitema
et
al
medicin
chemistri
antihepat
agent
antihav
antihdv
antihev
agent
furan
ring
found
inhibit
hav
k
valu
nm
compound
report
among
potent
nonpeptid
inhibitor
report
far
potent
compound
howev
screen
hav
ic
valu
ae
nm
model
studi
perform
compound
find
halopyridinyl
moieti
compound
fit
tightli
pocket
nitrogen
hydrogenbond
n
halogen
atom
point
toward
solvent
fig
carbonyl
oxygen
ester
oxyanion
hole
enzym
form
two
hydrogen
bond
one
nitrogen
nitrogen
similar
interact
compound
shown
sever
acut
respiratori
syndrom
sar
proteas
fig
substanti
theoret
studi
avail
hav
inhibitor
except
one
discuss
section
heteroaromat
ester
alreadi
discuss
hdv
caus
sever
liver
diseas
far
specif
therapi
develop
viru
fact
life
cycl
figur
dock
compound
hav
sar
b
case
compound
shown
three
hydrogen
bond
proteas
halopyridinyl
moieti
engulf
bind
pocket
reprint
permiss
huitema
et
al
bioorg
med
chem
copyright
elsevi
crucial
target
found
exploit
drug
design
howev
studi
point
prenyl
site
larg
delta
antigen
critic
determin
hdv
particl
assembl
delta
antigen
prenyl
pharmacolog
exploit
develop
antihdv
drug
context
benzodiazepin
peptidomimet
c
h
n
iupac
name
methyl
methylamino
acetyl
amino
develop
hdv
prenyl
inhibitor
drug
origin
synthes
specif
prenyltransferas
inhibitor
known
inhibit
prenyl
oncoprotein
hra
marster
et
al
glenn
et
al
later
studi
establish
could
use
antihdv
drug
author
studi
bile
acid
ba
antihdv
agent
yan
et
al
pereira
et
al
ba
gener
structur
shown
fig
steroid
acid
found
predominantli
bile
mammal
vertebr
polypeptid
known
sodiumtaurochol
cotransport
medicin
chemistri
antihepat
agent
antihav
antihdv
antihev
agent
polypeptid
ntcp
ba
transport
mediat
uptak
ba
hepatocyt
essenti
receptor
hbv
hdv
thu
interest
studi
extent
mechan
ba
affect
hdv
cell
entri
inhibitori
ba
inhibit
ntcpmediat
hdv
entri
hepatocyt
suggest
modul
ba
pool
may
affect
hdv
infect
hepatocyt
howev
reason
specul
conform
ntcp
favor
substrat
bind
viru
bind
may
mutual
affect
ba
act
substrat
ntpc
work
set
ba
pereira
et
al
demonstr
ba
inhibit
hdv
cell
entri
occur
like
competit
bind
ntcp
ba
larg
hbv
surfac
protein
shown
mediat
bind
hbv
hdv
ntcp
howev
effort
still
approv
drug
market
advanc
clinic
develop
stage
hdv
like
hav
inhibitor
mani
theoret
studi
avail
hdv
inhibitor
howev
compound
methyl
amino
one
develop
singh
et
al
antihdv
drug
virtual
screen
molecular
dock
studi
author
select
larg
set
hdv
replic
inhibitor
nation
centr
biotechnolog
inform
pubchem
compound
databas
ligand
molecul
abil
inhibit
replic
small
delta
antigen
shdag
protein
hdv
requir
hdv
rna
replic
vivo
kuo
et
al
dock
studi
threedimension
structur
model
shdag
protein
hdv
retriev
protein
model
databas
http
micaspuritpmdb
use
receptor
dock
studi
bind
mode
geometr
orient
compound
found
almost
ident
suggest
inhibitor
occupi
common
caviti
receptor
howev
compound
consid
potenti
candid
drug
hdv
inhibit
known
hev
respons
chronic
hepat
immunocompromis
patient
unfortun
still
establish
therapi
chronic
infect
rapidli
evolv
cirrhosi
requir
liver
transplant
haagsma
et
al
gerolami
et
al
kamar
et
al
howev
report
compound
ribavirin
may
antivir
effect
mallet
et
al
later
followup
ribavirin
cessat
found
short
although
compound
shown
inhibit
replic
wide
rang
rna
dna
virus
sidwel
et
al
patterson
fernandezlarsson
sustain
effect
hev
hardli
report
howev
kamar
et
al
report
ribavirin
monotherapi
could
inhibit
replic
hev
vivo
might
induc
sustain
virolog
respons
patient
chronic
hev
infect
determin
optim
durat
effect
ribavirin
therapi
studi
still
requir
author
studi
effect
anoth
antivir
compound
sofosbuvir
hev
infect
thi
et
al
found
inhibit
replic
hev
genotyp
subgenom
replicon
system
well
fulllength
infecti
clone
suggest
addit
antivir
effect
may
result
combin
ribavirin
thu
sofosbuvir
may
consid
addon
therapi
ribavirin
treatment
chronic
hepat
e
immunocompromis
patient
effort
find
new
categori
antihev
drug
nan
et
al
test
seri
phosphorodiamid
morpholino
oligom
pmo
abil
inhibit
hev
replic
liver
cell
pmo
nucleaseresist
singlestrand
dna
analog
contain
backbon
morpholin
ring
phosphorodiamid
linkag
summerton
pmo
medicin
chemistri
antihepat
agent
antihav
antihdv
antihev
agent
conjug
argininerich
cell
penetr
peptid
facilit
entri
cell
abe
et
al
summerton
peptideconjug
pmo
ppmo
water
solubl
readili
enter
cell
ppmo
studi
hev
inhibit
nan
et
al
found
display
potent
inhibit
hev
genotyp
replic
ppmo
target
start
site
region
hev
ppmo
observ
also
effect
inhibit
replic
genotyp
strain
liver
cell
conserv
natur
target
ppmo
overal
efficaci
suggest
compound
may
hevspecif
inhibitor
antivir
activ
across
multipl
hev
genotyp
addit
ppmo
three
ppmo
found
promis
develop
antihev
agent
ppmo
given
tabl
specif
seen
tabl
ppmo
complementari
sequenc
region
genom
subgenom
rna
respect
hand
complementari
sequenc
termin
region
utr
revers
complement
intend
interfer
synthesi
positivesens
genom
rna
ppmo
complementari
sequenc
end
region
genom
subgenom
rna
respect
tabl
complementari
sequenc
termin
region
utr
revers
complement
intend
interfer
synthesi
positivesens
genom
rna
nonsensesequ
ppmo
zhang
et
al
littl
agreement
hev
human
mrna
sequenc
use
neg
control
ppmo
fluorescein
conjug
end
use
ppmo
uptak
assay
ppmo
synthes
argininerich
cellpenetr
peptid
conjug
end
avi
biopharma
inc
corval
previous
describ
abe
et
al
substanti
theoret
work
avail
antihev
drug
chapter
present
theoret
experiment
studi
antihav
antihdv
antihev
drug
antihav
viru
well
exploit
follow
class
inhibitor
develop
inhibit
peptid
aldehyd
azaglutamin
ketoglutamin
deriv
azodicarboxamid
pseudoxazolon
serin
threonin
blacton
triazolo
pyridazin
heteroaromat
ester
theoret
studi
conduct
heteroaromat
ester
potent
compound
seri
dock
hav
found
halopyridinyl
moieti
complet
fit
pocket
enzym
nitrogen
hydrogen
bond
n
residu
enzym
carbonyl
oxygen
ester
oxyanion
hole
enzym
observ
form
two
hydrogen
bond
one
nitrogen
nitrogen
halogen
atom
found
point
toward
solvent
fig
antihdv
drug
delta
antigen
prenyl
inhibitor
ba
studi
inhibit
ntcpmediat
hdv
entri
hepatocyt
far
theoret
studi
antihdv
drug
concern
larg
set
hdv
replic
inhibitor
select
databas
dock
small
delta
antigen
shdag
protein
hdv
dock
studi
shown
bind
mode
geometr
orient
compound
almost
ident
suggest
inhibitor
occupi
common
caviti
receptor
compound
consid
potenti
candid
drug
hdv
inhibit
theoret
studi
avail
antihdv
drug
hev
therapi
seri
pmo
studi
pmo
could
conjug
argininerich
cell
penetr
peptid
facilit
entri
cell
peptideconjug
pmo
ppmo
found
potent
inhibitor
hev
genotyp
replic
studi
avail
antihev
drug
theoret
studi
almost
lack
